BRAF and melanoma: After 72 h of exposure, CDK4 inhibitor palbociclib reduced melanoma cell proliferation of Ma-Mel-123 cells with significantly higher efficiency than BRAF inhibitor vemurafenib (p = 0.0017) (Figure 3B).